BioNTech's Gotistobart Lung Cancer Data Gains Prestigious Publication

Significant clinical trial results for BioNTech's investigational lung cancer therapy, gotistobart, have been published in the high-impact journal Nature Medicine. The full Phase 3 data from the PRESERVE-003 study appeared in the publication on March 27, 2026, shortly after being presented at the European Lung Cancer Congress in Copenhagen.

Addressing a Major Unmet Need with Clear Survival Benefit

The published findings reveal a substantial survival advantage for a patient population with limited treatment options. The study focused on individuals with metastatic squamous non-small cell lung cancer (NSCLC) whose disease had progressed following both immunotherapy and platinum-based chemotherapy.

After a median follow-up period of 14.5 months, 55.6% of patients treated with gotistobart were alive. This compares to a survival rate of 23.8% for those in the control group receiving docetaxel chemotherapy. The median overall survival for the gotistobart cohort had not yet been reached at the time of analysis, while it stood at just under ten months for patients on docetaxel. This translates to a 54% reduction in the risk of death.

Market experts describe the medical need in this post-immunotherapy setting as "enormous," with few effective alternatives available for patients who are not candidates for targeted therapies.

Should investors sell immediately? Or is it worth buying BioNTech?

Safety Profile and Next Steps for the Clinical Program

On the safety front, immune-related adverse events were reported in 60% of patients receiving gotistobart, with 33.3% of those being grade 3 or higher in severity. The most common events included diarrhea, colitis, and elevated liver enzymes. Treatment discontinuation due to side effects occurred in 13.3% of the gotistobart group, versus 4.9% in the docetaxel arm.

A critical detail is that these published results originate from the initial, non-pivotal segment of a two-part trial. The decisive pivotal stage is already underway and actively enrolling participants. This next phase is evaluating a 6 mg/kg dose of gotistobart exclusively in patients with squamous cell carcinoma. The therapy's Orphan Drug designation from the U.S. FDA, coupled with the Nature Medicine publication, is seen as bolstering regulatory momentum for this subsequent step.

Pipeline Progress Contrasts with Challenging Market Sentiment

Beyond gotistobart, BioNTech shared additional pipeline updates in Copenhagen. Encouraging data was presented for pumitamig, a bispecific immunomodulator being developed in collaboration with Bristol Myers Squibb, supporting the ongoing global Phase 3 trial known as ROSETTA Lung-01 in small cell lung cancer. Initial clinical results for the HER3-targeted antibody-drug conjugate candidate BNT326 from a Phase 2 study also demonstrated anti-tumor activity alongside a favorable safety profile.

BioNTech at a turning point? This analysis reveals what investors need to know now.

These scientific advancements are unfolding against a backdrop of difficult equity market conditions for BioNTech. Since early March, a trio of negative developments has weighed on the share price: the announced departure of co-founders Ugur Sahin and Özlem Türeci by the end of 2026; a net loss of approximately €305 million for the fourth quarter of 2025; and a 2026 revenue forecast ranging between €2.0 billion and €2.3 billion, which falls notably below the analyst consensus estimate of around €2.69 billion. The stock is currently trading near its 52-week low.

According to MarketBeat, the average analyst rating across 18 brokerages is "Moderate Buy," with a consensus price target of $133.73. The company maintains a strong cash position of €17.2 billion. Looking ahead, BioNTech anticipates having 15 active Phase 3 trials by the end of 2026, along with seven late-stage data readouts. The Nature Medicine publication for the PRESERVE-003 study marks the first of these to achieve full peer-reviewed status.

Ad

BioNTech Stock: New Analysis - 31 March

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

US09075V1026 | BIONTECHS | boerse | 69033709 |